Brokers Issue Forecasts for CNTA Q1 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Centessa Pharmaceuticals in a report released on Monday, March 24th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04.

A number of other analysts also recently commented on the stock. Guggenheim reiterated a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday. Morgan Stanley restated an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock opened at $14.54 on Wednesday. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.92 billion, a PE ratio of -9.50 and a beta of 1.54. The company’s 50-day moving average price is $16.49 and its two-hundred day moving average price is $16.42.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth about $1,609,000. State Street Corp acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $777,000. Ally Bridge Group NY LLC bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $4,951,000. Finally, Lord Abbett & CO. LLC acquired a new position in Centessa Pharmaceuticals in the third quarter worth approximately $4,305,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Activity

In other news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total value of $867,350.00. Following the completion of the sale, the chief executive officer now directly owns 429,398 shares of the company’s stock, valued at $6,771,606.46. This represents a 11.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Tia L. Bush sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now directly owns 121,503 shares in the company, valued at $2,048,540.58. The trade was a 8.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock worth $4,309,568 over the last 90 days. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.